GlassScriptPhysician profile
Bryan Robert Anderson
NPI 1578828224
$4,400.94
in general payments reported to CMS, 2019-2025
27 companies · $818 in 2025
The $818 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $402 · 2021: $351 · 2022: $657 · 2023: $970 · 2024: $1,007 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,359 · Education: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,359.45 |
| Education | $435.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $787.22 | 2019-2025 | Trelegy Ellipta, Nucala |
| Electromed, INC. | $671.16 | 2022-2025 | Smartvest |
| Sanofi-Aventis U.S. LLC | $357.71 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.53 | 2019-2025 | Ofev |
| United Therapeutics Corporation | $310.18 | 2020-2025 | Orenitram, Tyvaso, Tyvaso |
| Stryker Corporation | $308.24 | 2023 | Variax, Gamma, T2 Alpha |
| Actelion Pharmaceuticals US, INC. | $235.14 | 2022-2025 | Opsumit, Uptravi |
| Insmed, INC. | $214.78 | 2021-2025 | Arikayce |
| Astrazeneca Pharmaceuticals LP | $185.05 | 2019-2024 | Airsupra, Tezspire, Fasenra |
| Genzyme Corporation | $153.22 | 2021-2025 | |
| Baxter Healthcare | $147.27 | 2022-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Covidien LP | $131.82 | 2020 | |
| Heron Therapeutics, INC. | $117.01 | 2024 | Zynrelef |
| Pfizer INC. | $61.68 | 2023 | |
| Medtronic, INC. | $44.96 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $41.15 | 2019-2023 | Yupelri |
| Merck Sharp & Dohme LLC | $40.51 | 2023-2025 | Zerbaxa |
| Philips North America LLC | $39.31 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Medline Industries LP | $37.63 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.16 | 2024 | Glassia |
| Genentech USA, INC. | $25.18 | 2021 | |
| Verona Pharma, INC. | $23.08 | 2025 | Ohtuvayre |
| Boston Scientific Corporation | $23.08 | 2023 | |
| Amgen INC. | $22.83 | 2024 | Tavneos |
| Grifols USA, LLC | $18.19 | 2023 | Prolastin-C Liquid |
| Vifor Pharma, INC. | $18.13 | 2025 | Veltassa |
| Regeneron Healthcare Solutions, INC. | $13.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.